|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Association between the estrogen receptor alpha A908G mutation and outcomes in invasive breast cancer.
|
17545528 |
2007 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Differential expression of VEGF-A mRNA by 17beta-estradiol in breast tumor cells lacking classical ER-alpha may be mediated through a variant form of ER-alpha.
|
15532726 |
2004 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Observations on the presence of E domain variants of estrogen receptor-alpha in the breast tumors.
|
16941532 |
2006 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Moreover, the increased risk conferred by the minor FGFR2 allele associates most strongly in oestrogen receptor alpha positive (ERα) breast tumours, suggesting a potential interaction between ERα and FGFR signalling.
|
24265722 |
2013 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Analysis of the ERalpha germline PvuII marker in breast cancer risk.
|
18301357 |
2008 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The sensitive NMBA assay was validated with well-characterized ER(+) breast cancer cell lines and also identified functional variants of ER among breast tumor biopsy specimens.
|
11084868 |
2000 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
GD3 is upregulated in approximately half of all invasive ductal breast carcinoma cases, and enhanced expression of GD3 synthase (GD3S, alpha-N-acetylneuraminide alpha-2,8-sialyltransferase) in estrogen receptor-negative breast tumors, was shown to correlate with reduced overall patient survival.
|
28537895 |
2017 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
A SERD- or SSH-palbociclib combination has therapeutic potential in breast tumors resistant to endocrine therapies or those expressing ESR1 mutations.
|
25991817 |
2015 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
ESR1 and EGF genetic variation in relation to breast cancer risk and survival.
|
18271972 |
2008 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Subgroup analyses by menopausal status, hormone receptor status of breast tumors (estrogen receptor [ER], progesterone receptor [PR] and human epidermal growth factor receptor 2 [HER2]), alcohol intake and MTHFR polymorphisms (677C > T and 1298A > C) were also performed.
|
27905104 |
2017 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
CLINVAR |
Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer.
|
24398047 |
2014 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
The estrogen receptor-alpha A908G (K303R) mutation occurs at a low frequency in invasive breast tumors: results from a population-based study.
|
16280033 |
2005 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Impaired p53 function leads to centrosome amplification, acquired ERalpha phenotypic heterogeneity and distant metastases in breast cancer MCF-7 xenografts.
|
18264135 |
2008 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
As metabolism is the key factor in altering cellular estrogens, thereby influencing breast tumor growth, we investigated the effects of RES on the formation of estrogen metabolites, namely 4-androstene-3,17-dione (AD), dehydroepiandrosterone (DHEA), dehydroepiandrosterone-3-<i>O</i>-sulfate (DHEA-S), estrone (E1), estrone-3-sulfate (E1-S), 17β-estradiol (E2), 17β-estradiol-3-<i>O</i>-(β-D-glucuronide) (E2-G), 17β-estradiol-3-<i>O</i>-sulfate (E2-S), 16α-hydroxy-17β-estradiol (estriol, E3), and testosterone (T) in ERα- MDA-MB-231 and ERα+ MCF-7 cells.
|
30042681 |
2018 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Recent studies have confirmed that ESR1 point mutations frequently occur in metastatic breast tumors that are refractory to endocrine therapy, and suggest the development of novel strategies that may be more effective in controlling ER signaling and benefit patients with recurrent and metastatic disease.
|
26183887 |
2015 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Association of estrogen receptor alpha polymorphisms with breast cancer risk in older Caucasian women.
|
15856463 |
2005 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Association of repeat polymorphisms in the estrogen receptors alpha, beta (ESR1, ESR2) and androgen receptor (AR) genes with the occurrence of breast cancer.
|
17904846 |
2008 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
To understand the relationship between CD44 gene expression and an established variable associated with aggressive behaviour in human breast cancer, we have studied a panel of 6 breast cell lines and 40 breast tumors selected primarily on the basis of estrogen receptor (ER) status.
|
9131272 |
1997 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Breast cancer risk associated with genotypic polymorphism of the genes involved in the estrogen-receptor-signaling pathway: a multigenic study on cancer susceptibility.
|
16502042 |
2006 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
The estrogen receptor alpha gene and breast cancer risk (The Netherlands).
|
16215870 |
2005 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
BRCA1-mutant breast tumors are typically estrogen receptor alpha (ER alpha) negative, whereas most sporadic tumors express wild-type BRCA1 and are ER alpha positive.
|
18000219 |
2007 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Alterations in the estrogen receptor alpha mRNA in the breast tumors of African American women.
|
10815765 |
2000 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Recent evidence suggests that the progression to hormone resistance in some breast tumors is due to mutations in the estrogen receptor (ER).
|
1362141 |
1992 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The relative levels of certain ER variant mRNAs have been observed to increase with breast tumor progression.
|
8614007 |
1996 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Breast tumors with p53 mutations are generally estrogen receptor negative and are associated with compromised distant disease free survival.
|
10699900 |
2000 |